You can't be distracted! I turn my head for a second and ARV-766 trial has got some results to post!
I will be traveling on monday, but I will try to check if those data are good!
You can't be distracted! I turn my head for a second and ARV-766 trial has got some results to post!
I will be traveling on monday, but I will try to check if those data are good!
my believe ARV-766 will not work who failed zytiga (Abiraterone acetate) in past
Source link :
scr.zacks.com/news/news-det...
Here is the screenshot from data perspective, They did not treat anyone who failed zytiga
check the row that said " prior Abiraterone" it is 0%. It means to me they did not treat who failed zytiga
Am i correct ? Please help me to understand as well.
I think you are right, but I don't know if it's because it fails to treat them or because they wanted a direct comparison with Affirm and Prevail trials
Got it now!
"AUA 2024: ARV-766, a PROTAC Androgen Receptor Degrader, Combined with Abiraterone in Novel Hormonal Agent (NHA)-Naïve Metastatic Prostate Cancer: Phase 1 Cohort (Part C) of a Phase 1/2 Study"
It's + Abiraterone in the study and it's NHA naive....so no previous Abi
Check it here: urotoday.com/conference-hig...
I was in part 2 of the trial, 300mg. Great early results with PSA reduction of 60% at 4 weeks. Unfortunately, PSA then began to rise and ended trial participation when PSA kept rising & scans showed progression. I think the idea of hitting the cancer with multiple hammers all at once is the way to go. I believe (& my Dr. agrees) that ARV-766 killed a subset of cancer cells, which left room for those that survived to grow (less competition for resources, etc). I think same occurred (for me) with Pluvicto.